Thrombin-Activatable Fibrinolysis Inhibitor Levels in Patients with Non–Small-Cell Lung Cancer

Koldaş, Macit; Gümüş, Mahmut; Şeker, Mesut; Seval, Hatice; Karaoglu, Hulya; Dane, Faysal; Kural, Alev; Gümüş, Alper; Salepçi, Taflan; Turhal, Nazım Serdar

doi:10.3816/clc.2008.n.017

Cited by 14 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, 3 of the 4 TAFI activities of greatest magnitude were found in dogs with malignant neoplasms. In people significantly increased TAFI activities and plasma antigen concentrations have been found to contribute to the hypercoagulable state in various types of lung cancers 9,10 . A recent study of 30 dogs with neoplasia demonstrated that the majority of dogs with malignant neoplasms are hypercoagulable 20 .…”

Section: Discussionmentioning

confidence: 99%

“…In people increased TAFI antigen has been associated with increased risk of venous thrombosis and recurrent pulmonary thromboembolism 7,8 and has been found in various diseases with increased thrombotic potential, such as cancer, 9,10 inflammatory bowel disease, 11 and polycystic ovary syndrome 12 . At the other end of the scale, decreased TAFI activity has been implicated as a contributor of bleeding diathesis in people with acute promyelocytic leukemia 13 and in people with factor XI deficiency 4,14 .…”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

ORIGINAL RESEARCH: Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs

Jessen

Wiinberg

Kjelgaard‐Hansen

et al. 2010

Veterinary Clinical Pathology

View full text Add to dashboard Cite

Background: In people, increased thrombin-activatable fibrinolysis inhibitor (TAFI) antigen has been associated with increased risk of thrombosis, and decreased TAFI may contribute to bleeding diathesis. TAFI activity in dogs has been described in experimental models, but not in dogs with spontaneous disease. Objective: The aim of this study was to compare TAFI activity in healthy dogs with TAFI activity in dogs with spontaneous disease. Methods: Plasma samples from 20 clinically healthy Beagles and from 35 dogs with various diseases were analyzed using a commercial chromogenic assay that measured TAFI activity relative to activity in standardized pooled human plasma. Results: Median TAFI activity for the 20 Beagles was 46.1% (range 32.2-70.8%) compared with 62.6% (29.1-250%) for the 35 diseased dogs, and 14/35 (40%) had TAFI activities 4 the upper limit for controls. The highest individual activities (4 225%) were in 3 dogs with malignant neoplasms and 1 dog with thrombocytopenia. For data grouped by diagnosis, median TAFI activity was 61.7% for benign neoplasia (n = 5), 64.9% for malignant neoplasia (n = 8), 75.5% for Angiostrongylus vasorum infection (n = 4), 68.8% for bacterial sepsis (n = 7), and 58.7% for miscellaneous diseases (n = 11). Compared with TAFI activity in control dogs, median TAFI activity was significantly increased only in the group of dogs with bacterial sepsis. Conclusion: Bacterial sepsis was associated with significantly increased TAFI activity, and individual dogs with increased TAFI activities were found in all disease groups. The role of TAFI in the pathogenesis of hemostatic disorders in dogs and its value as a prognostic indicator deserve further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 90%

ORIGINAL RESEARCH: Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs

Jessen

Wiinberg

Kjelgaard‐Hansen

et al. 2010

Veterinary Clinical Pathology

View full text Add to dashboard Cite

show abstract

“…This connection may result from the cancer itself or the therapeutic treatments used. Gastrointestinal, lung and pancreatic cancers are considered more likely to induce hyper-coagulation in patients [2][3][4]. Rather than being merely a trigger of increased thromboembolic events, cancer-induced haemostatic activity has been shown to promote cancer cell dissemination [5][6][7].…”

Section: Introductionmentioning

confidence: 98%

Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer

Chen

Wang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Fibrin deposition and remodelling of the extracellular matrix are important early steps in tumour metastasis. The D-dimer value is an indicator of intravascular fibrin formation and degradation. Thus, the D-dimer value may be a predictor of the malignant involvement of lymph nodes in operable non-small cell lung cancer (NSCLC) patients. The study comprised 142 highly suspected lung cancer patients scheduled to undergo pneumonectomy, lobectomy or wedge resection. Of the 142 patients, 124 were subsequently diagnosed as NSCLC, and 18 were subsequently diagnosed as benign lung disease by histological examination. Preoperative plasma D-dimer values were quantified, and the relationship between plasma D-dimer and clinical variables including tumour size, involvement of lymph nodes and clinical stage was examined using Spearman correlation coefficients and χ (2) tests. The median plasma D-dimer values were statistically higher in NSCLC patients with malignant lymph nodes than in those who suffered either benign lung disease or carcinoma in situ (Kruskal-Wallis test; P = 0.001). Plasma D-dimer values were significantly correlated with clinical stage (ANOVA; P = 0.009). An obvious relationship was observed between elevated D-dimer (>0.475 mg/L fibrinogen equivalent units) and malignant lymph node involvement (χ (2) test; P = 0.0000). This correlation suggests that the plasma D-dimer value is a clinically important predictor for the malignant involvement of lymph nodes in operable NSCLC.

show abstract

“…The knockout mouse study has indicated that TAFI deficiency has no discernable effect on primary tumor growth and metastasis [16]. Nevertheless, increased levels of circulating TAFI have been detected in patients with small or nonsmall cell lung carcinoma [17,18], whereas reduced TAFI activity has been observed in patients suffering from acute promyelocytic leukemia [19].…”

Section: Introductionmentioning

confidence: 99%

Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer

Zhang

et al. 2013

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Impairment of fibrinolytic function plays an important role in the mechanism of thrombotic disorders in cancer patients. Thrombin-activatable fibrinolysis inhibitor (TAFI) has an antifibrinolytic effect as it can remove partially degraded fibrin C-terminal lysine residues and reduce plasmin formation. The purpose of this study was to investigate whether blood TAFI levels and TAFI Thr325Ile polymorphism could be a risk marker of breast cancer. The plasma TAFI antigen (Ag) level was determined using ELISA assay in 256 patients with breast cancer and 192 healthy controls. TAFI Thr325Ile (rs1926447) polymorphism was genotyped in both patients and control groups using PCR-restriction fragment length polymorphism (PCR-RFLP) and sequencing. The results showed that TAFI Ag levels were significantly higher in breast cancer patients than those in controls (100.6 ± 15.2 and 82.7 ± 11.2%, P < 0.001). TAFI Ag levels were correlated with metastasis of breast cancer (P < 0.001). The Thr/Ile (CT) and Ile/Ile (TT) genotypes were found more frequently in patients group compared with the control group [odds ratio (OR) 2.106; (95% confidence interval, CI 1.379-3.217); P < 0.001]. The high-risk T alleles frequency was also higher in patients compared with healthy controls [OR 1.718; (95% CI 1.316-2.243); P < 0.001]. The polymorphism was significantly correlated with TAFI Ag levels in either group (P < 0.001). The Ile/Ile (TT) genotype had the lowest TAFI Ag level, whereas the Thr/Thr (CC) had the highest one. In conclusion, the plasma TAFI levels and TAFI Thr325Ile genotypes were associated with breast cancer patients in Chinese Han populations and could be considered as the risk indicators of breast cancer.

show abstract

Thrombin-Activatable Fibrinolysis Inhibitor Levels in Patients with Non–Small-Cell Lung Cancer

Cited by 14 publications

References 14 publications

ORIGINAL RESEARCH: Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs

ORIGINAL RESEARCH: Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs

Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer

Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer

Contact Info

Product

Resources

About